IP Library › Granted Patent US 12,285,476
Granted Patent B2
US 12,285,476 · App. 17/578,049 · Granted Apr 29, 2025

Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody

Inventors: Nahoko Baileykobayashi (Tsukuba, JP); Tetsuhiko Yoshida (Tsukuba, JP)
Assignee: TOAGOSEI CO., LTD.
A61K39/12C07K14/005C07K16/1003A61K39/00C12N2770/20022C12N2770/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,476
App. No.
17/578,049
Granted
Apr 29, 2025
Kind
B2
Abstract

The present disclosure provides a synthetic peptide containing an amino acid sequence that can be used to produce antibodies against proteins derived from a new coronavirus (SARS-CoV-2). The synthetic peptide provided herein is recognized as an antigen relative to at least one mammal, contains an amino acid sequence which is LNESLIDLQELGKYEQYIKWP (SEQ ID NO: 1), and has a total number of amino acid residues of 25 or less.

Claims (11)

1. An artificial synthetic peptide recognized as an antigen relative to at least one mammal, wherein

the artificial synthetic peptide consists of an amino acid sequence: LNESLIDLQELGKYEQYIKWP (SEQ ID NO: 1) and the N-terminal amino group of the artificial synthetic peptide is an N-acetylated amino group.

2. A composition that contains a moiety recognized as an antigen relative to at least one mammal, the composition comprising:

an artificial synthetic peptide consisting of an amino acid sequence: LNESLIDLQELGKYEQYIKWP (SEQ ID NO: 1); and

a carrier protein, wherein the N-terminal amino group of the artificial synthetic peptide is an N-acetylated amino group and the carrier protein is bound to the C-terminal side or the N-terminal side of the amino acid sequence constituting the artificial synthetic peptide through a cross-linking agent.

3. A method for producing an anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibody, the method comprising:

preparing a composition comprising an artificial synthetic peptide consisting of an amino acid sequence: LNESLIDLQELGKYEQYIKWP (SEQ ID NO: 1) and a carrier protein, wherein the N-terminal amino group of the artificial synthetic peptide is an N-acetylated amino group and the carrier protein is bound to the C-terminal side or the N-terminal side of the amino acid sequence of the artificial synthetic peptide through a cross-linking agent; and

administering the composition to a subject to produce the antibody against the peptide.

4. The method according to claim 3 , wherein the subject is a mammal.

5. The composition according to claim 2 , wherein the carrier protein is keyhole limpet hemocyanin (KLH), ovalbumin (OVA), or bovine serum albumin (BSA).

6. The method according to claim 3 , wherein the carrier protein is keyhole limpet hemocyanin (KLH), ovalbumin (OVA), or bovine serum albumin (BSA).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2022
From: BAILEYKOBAYASHI, NAHOKO; YOSHIDA, TETSUHIKO
To: TOAGOSEI CO., LTD.
Reel/Frame 058682/0256 →
Priority Claims (1)
JP 2021-012663 · Jan 29, 2021 · national
Continuity (1)
Related Publication 20220242916A1 · Aug 4, 2022
References Cited (27)
US 7491793B2 · Garry · 2009 [cited by examiner]
US 10787501B1 · Babb · 2020 [cited by examiner]
US 11241493B2 · Rauch · 2022 [cited by examiner]
US 11384122B2 · Langedijk · 2022 [cited by examiner]
US 20210009718A1 · Ambrogelly · 2021 [cited by examiner]
US 20210379181A1 · Rauch · 2021 [cited by examiner]
US 20230357328A1 · Hikichi · 2023 [cited by examiner]
US 20240067679A1 · Kiyotani · 2024 [cited by examiner]
CN 111647054A · 2020 [cited by examiner]
WO 2017130716A1 · 2017 [cited by applicant]
WO WO2021188969A2 · 2021 [cited by examiner]
WO WO2022090752A1 · 2022 [cited by examiner]
Li, W., Ran, Y., Li, M., Zhang, K., Qin, X., Xue, X., Zhang, C., Hao, Q., Zhang, W., & Zhang, Y. (2013). Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies. BMC Biotechnology, 13(1), 77-77. (Yea… [cited by examiner]
Aguilar, A. et al. (2014). Study of Peptide Mimetics of Hepatitis A Virus Conjugated to Keyhole Limpet Hemocyanin and as Multiple Antigen Peptide System. International Journal of Peptide Research and Therapeutics, 20(1)… [cited by examiner]
Wang, L., Fu, S., Cao, Y., Zhang, H., Feng, Y., Yang, W., Nie, K., Ma, X., & Liang, G. (2017). Discovery and genetic analysis of novel coronaviruses in least horseshoe bats in southwestern China. Emerging microbes & inf… [cited by examiner]
Zhou, H. et al. (2020). A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein. Current biology : CB, 30(11), 2196-2203.e3. (Year: 2020). [cited by examiner]
Zhou, H. et al. (2020). Correction: A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein. Current biology : CB, 30(19), 3896. (Year: 2020). [cited by examiner]
Cokerton et al. GenBank Accession No. UYE28336.1. Direct Submission. Submitted Oct. 13, 2022. (Year: 2022). [cited by examiner]
Garry and Wilson. GenBank Accession No. ACP58571.1. Seq ID No. 29 from U.S. Pat. No. 7,491,793. (Year: 2009). [cited by examiner]
Langedijk et al. GenBank Accession No. WIU06475.1. Seq ID No. 210 from U.S. Pat. No. 11,384,122. (Year: 2020). [cited by examiner]
Rauch et al. GenBank Accession No. WFJ29710.1. Seq ID No. 13,539 from U.S. Pat. No. 11,241,493. (Year: 2020). [cited by examiner]
Zhao et al. CN 111647054 A. Machine Translation. (Year: 2020). [cited by examiner]
Tohidinia, M., & Sefid, F. (2020). Identification B and T-Cell epitopes and functional exposed amino acids of S protein as a potential vaccine candidate against SARS-CoV-2/COVID-19. Microbial Pathogenesis, 148, 104459-1… [cited by examiner]
Li, Y. et al. (2020). Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cellular & Molecular Immunology/Cellular & Molecular Immunology, 17(10), 1095-1097. (Year: 2020). [cited by examiner]
Su, Wen, D., Yang, Q., Zhang, Y., Liu, C., & Wang, L. (2007). Comparison of phage pVIII and KLH as vector in inducing the production of cytokines in C57BL/6J mice. Vaccine, 25(6), 970-975. (Year: 2007). [cited by examiner]
Wu, F., Zhao, S., Yu, B. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269 (2020). https://doi.org/10.1038/s41586-020-2008-3. [cited by applicant]
Xia, S. Zhu, Y., Liu, M. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 17, 765-767 (2020). https://doi.org/10.1038/s41423-020-0374-2. [cited by applicant]